{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:29:10Z","timestamp":1777120150847,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00520-022-07138-8","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T11:03:33Z","timestamp":1652785413000},"page":"8511-8517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5508-1472","authenticated-orcid":false,"given":"Thura Win","family":"Htut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-1097","authenticated-orcid":false,"given":"Kyaw Zin","family":"Thein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-0379","authenticated-orcid":false,"given":"Kyaw Lwin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5201-731X","authenticated-orcid":false,"given":"Thein Hlaing","family":"Oo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"issue":"1","key":"7138_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.V62.1.14.14","volume":"62","author":"FR Rickles","year":"1983","unstructured":"Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau\u2019s syndrome revisited. Blood 62(1):14\u201331","journal-title":"Blood"},{"issue":"6","key":"7138_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809\u2013815. https:\/\/doi.org\/10.1001\/archinte.160.6.809","journal-title":"Arch Intern Med"},{"issue":"6","key":"7138_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715\u2013722. https:\/\/doi.org\/10.1001\/jama.293.6.715","journal-title":"JAMA"},{"issue":"7","key":"7138_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9(7):e1001275. https:\/\/doi.org\/10.1371\/journal.pmed.1001275","journal-title":"PLoS Med"},{"issue":"3","key":"7138_CR5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x","journal-title":"J Thromb Haemost"},{"issue":"10","key":"7138_CR6","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581. https:\/\/doi.org\/10.1016\/S1470-2045(19)30336-5","journal-title":"Lancet Oncol"},{"issue":"5","key":"7138_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461","journal-title":"J Clin Oncol"},{"issue":"10","key":"7138_CR8","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907. https:\/\/doi.org\/10.1182\/blood-2007-10-116327","journal-title":"Blood"},{"key":"7138_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer N, Culakova E, Poniewierski MS, Wolff D, Lyman GH (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practive. J Natl Compr Canc Netw 6:109\u2013118. https:\/\/doi.org\/10.6004\/jnccn.2008.0012","journal-title":"J Natl Compr Canc Netw"},{"issue":"24","key":"7138_CR10","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","volume":"116","author":"C Ay","year":"2010","unstructured":"Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R et al (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377\u20135382. https:\/\/doi.org\/10.1182\/blood-2010-02-270116","journal-title":"Blood"},{"issue":"3","key":"7138_CR11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291\u2013292. https:\/\/doi.org\/10.1007\/s11739-012-0784-y","journal-title":"Intern Emerg Med"},{"issue":"41","key":"7138_CR12","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1055\/s-0033-1349608","volume":"138","author":"U Pelzer","year":"2013","unstructured":"Pelzer U, Sinn M, Stieler J, Reiss H (2013) Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 138(41):2084\u20132088. https:\/\/doi.org\/10.1055\/s-0033-1349608","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"7138_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","volume":"22","author":"CA Cella","year":"2017","unstructured":"Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E et al (2017) Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 22(5):601\u2013608. https:\/\/doi.org\/10.1634\/theoncologist.2016-0246","journal-title":"Oncologist"},{"key":"7138_CR14","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1634\/theoncologist.2019-0510","volume":"25","author":"J Godinho","year":"2020","unstructured":"Godinho J, Casa-Nova M, Moreira-Pinto J, Simoes P, Paralta Branco F, Leal-Costa L et al (2020) ONKOTEV score as a predictive tool for thromboembolic events in pancreatic cancer \u2013 a retrospective analysis. Oncologist 25:e284\u2013e290. https:\/\/doi.org\/10.1634\/theoncologist.2019-0510","journal-title":"Oncologist"},{"issue":"10","key":"7138_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","volume":"22","author":"GT Gerotziafas","year":"2017","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S et al (2017) A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist 22(10):1222\u20131231. https:\/\/doi.org\/10.1634\/theoncologist.2016-0414","journal-title":"Oncologist"},{"issue":"7","key":"7138_CR16","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","volume":"5","author":"I Pabinger","year":"2018","unstructured":"Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM et al (2018) A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 5(7):e289\u2013e298. https:\/\/doi.org\/10.1016\/S2352-3026(18)30063-2","journal-title":"Lancet Haematol"},{"key":"7138_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","volume":"150","author":"N van Es","year":"2017","unstructured":"van Es N, Franke VF, Middledorp S, Wilmink JW, Buller HR (2017) The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res 150:30\u201332. https:\/\/doi.org\/10.1016\/j.thromres.2016.12.013","journal-title":"Thromb Res"},{"issue":"10","key":"7138_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s12094-014-1165-y","volume":"16","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2014","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Garc\u00eda Alfonso P, Rup\u00e9rez Blanco AB, P\u00e9rez Ram\u00edrez S, Blanco Codesido M, Mart\u00edn JM (2014) Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana\u2019s predictive model. Clin Transl Oncol 16(10):927\u2013930. https:\/\/doi.org\/10.1007\/s12094-014-1165-y","journal-title":"Clin Transl Oncol"},{"issue":"18","key":"7138_CR19","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S et al (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 33(18):2028\u20132034. https:\/\/doi.org\/10.1200\/JCO.2014.55.1481","journal-title":"J Clin Oncol"},{"issue":"9","key":"7138_CR20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F et al (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283\u20131292. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.017","journal-title":"Eur J Cancer"},{"key":"7138_CR21","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj S, Zhou X, Varadhacgary GR, Milind J, Fogelman D, Shroff R et al Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE. Blood, 2013. 122(21): p. 580. https:\/\/ashpublications.org\/blood\/article\/122\/21\/580\/94207\/, Accessed August 15, 2021","DOI":"10.1182\/blood.V122.21.580.580"},{"issue":"10","key":"7138_CR22","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavana L et al (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943\u2013949. https:\/\/doi.org\/10.1016\/S1470-2045(09)70232-3","journal-title":"Lancet Oncol"},{"issue":"7","key":"7138_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P et al (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366(7):601\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1108898","journal-title":"N Engl J Med"},{"issue":"8","key":"7138_CR24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Reiss H, Wun T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728. https:\/\/doi.org\/10.1056\/NEJMoa1814630","journal-title":"N Engl J Med"},{"key":"7138_CR25","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1002\/cam4.3269","volume":"9","author":"S Vadhan-Raj","year":"2020","unstructured":"Vadhan-Raj S, McNamara MG, Venerio M, Reiss H, O\u2019Reilly EM, Overman MJ et al (2020) Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med 9:6196\u20136204. https:\/\/doi.org\/10.1002\/cam4.3269","journal-title":"Cancer Med"},{"issue":"8","key":"7138_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Takalagis V, Shivakumar S, Schattner A et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711\u2013719. https:\/\/doi.org\/10.1056\/NEJMoa1814468","journal-title":"N Engl J Med"},{"key":"7138_CR27","doi-asserted-by":"publisher","DOI":"10.1055\/a-1548-4847","author":"JM Riedl","year":"2021","unstructured":"Riedl JM, Schwarzenbacher E, Moik F, Horvath L, Gantschnigg A, Renneberg F et al (2021) Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine\/nab-paclitaxel. Thromb Haemost. https:\/\/doi.org\/10.1055\/a-1548-4847","journal-title":"Thromb Haemost"},{"key":"7138_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2147\/PPA.S58595","volume":"8","author":"S Seaman","year":"2014","unstructured":"Seaman S, Nelson A, Noble N (2014) Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 8:453\u2013461. https:\/\/doi.org\/10.2147\/PPA.S58595","journal-title":"Patient Prefer Adherence"},{"key":"7138_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/PPA.S79373","volume":"9","author":"S Noble","year":"2015","unstructured":"Noble S, Prout H, Nelson A (2015) Patients\u2019 Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 9:337\u2013345. https:\/\/doi.org\/10.2147\/PPA.S79373","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"7138_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00520-019-04815-z","volume":"28","author":"P Debourdeau","year":"2020","unstructured":"Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N et al (2020) Factors influencing patient\u2019s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study. Support Care Cancer 28(1):287\u2013293. https:\/\/doi.org\/10.1007\/s00520-019-04815-z","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07138-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:11:27Z","timestamp":1664183487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07138-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7138"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07138-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Thein Hlaing Oo served on the advisory board of Bristol-Myers Squibb. Thura Win Htut, Kyaw Zin Thein, and Kyaw Lwin Aung declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}